nivolumab,ipilimumab
bms
['diciple']
 presenting some intriguing data from diciple trial where rx either stopped or discontinued after 6 months disease control. statistical power lost due to small numbers but interestingly no detriment to discontinuing at 6mo and less tox! #esmo22 
Medical Oncologist, Translational Researcher, Peter Mac. Tweets are my own opinions. Musician (@mayhemtomi) https://t.co/f3ccD2Ml7v